Increased bactericidal activity as documented by serum bactericidal titers for a triple combination of cell wall active agents against gentamicin-resistant enterococci.
Infections caused by entercocci have become increasingly difficult to treat because these bacteria are becoming increasingly resistant to commonly used antibiotics such as ampicillin, gentamicin and vancomycin. A consensus for an optimal therapy of enterococcal infections caused by resistant isolates has not yet been determined. We present a patient with prolonged enterococcal sepsis in whom a combination of ampicillin, vancomycin and imipenem was ultimately successful in suppressing enterococcal bacteremia. The enhanced activity of this triple combination was documented by the results of serial serum bactericidal titers.
Antony
S J
SJ
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
Matherin
P
P
Stratton
C
C
D000328:Adult; D000667:Ampicillin / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000494:pharmacology / Q000627:therapeutic use*; D013293:Enterococcus faecalis / Q000187:drug effects* / Q000302:isolation & purification; D005260:Female; D005839:Gentamicins / Q000494:pharmacology / Q000627:therapeutic use; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D015378:Imipenem / Q000494:pharmacology / Q000627:therapeutic use; D010406:Penicillins / Q000494:pharmacology / Q000627:therapeutic use; D015610:Serum Bactericidal Test; D013845:Thienamycins / Q000494:pharmacology / Q000627:therapeutic use; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D010406:Penicillins; D013845:Thienamycins; D014640:Vancomycin; D015378:Imipenem; D000667:Ampicillin